Roughly 2.3 million new breast cancer cases are diagnosed worldwide each year, making it the most common cancer among women globally. In the United States alone, more than 4 million women are currently living with a history of breast cancer. That number includes people in active treatment, long-term survivors, and those managing metastatic disease.
Global Numbers at a Glance
In 2022, the most recent year with complete global data, 2,296,840 new breast cancer cases and 666,103 deaths were recorded worldwide. Those numbers are expected to climb. The Global Burden of Disease Study 2023 projects that new cases will rise by a third, from 2.3 million to over 3.5 million by 2050. Annual deaths are forecast to increase even more sharply, up 44% from roughly 764,000 to 1.4 million over the same period. Population growth and aging are the primary drivers, particularly in low- and middle-income countries where screening and treatment access remain limited.
Breast Cancer in the United States
The U.S. has one of the largest populations of breast cancer survivors in the world. As of January 2022, an estimated 4,055,775 women were living after a breast cancer diagnosis. That figure spans everyone from a person freshly out of surgery to someone 30 years past treatment. About 1 in every 100 breast cancer cases diagnosed in the U.S. is found in a man, a proportion that’s stayed relatively stable over time.
An estimated 170,000 women in the U.S. are currently living with metastatic breast cancer, the stage where the disease has spread beyond the breast and nearby lymph nodes to other organs. This group represents a small fraction of total survivors, but their treatment needs are ongoing and intensive.
Risk by Age
Breast cancer risk increases significantly with age. According to the National Cancer Institute, the chance of being diagnosed over the next 10 years looks like this at each age:
- Age 30: 0.49%, or about 1 in 204
- Age 40: 1.55%, or about 1 in 65
- Age 50: 2.40%, or about 1 in 42
- Age 60: 3.54%, or about 1 in 28
- Age 70: 4.09%, or about 1 in 24
The jump between your 30s and 40s is the steepest. By age 60, your 10-year risk is roughly seven times higher than it was at 30. This is why most screening guidelines recommend starting mammograms in your 40s, with the strongest benefit seen in women 50 and older.
Types of Breast Cancer by Subtype
Not all breast cancers behave the same way. Tumors are classified by whether they’re fueled by hormones (estrogen or progesterone) and whether they overproduce a growth-promoting protein called HER2. The breakdown of cases in the U.S., based on SEER data from 2019 to 2023:
- Hormone receptor-positive, HER2-negative: About 70% of cases. This is by far the most common subtype and generally has the best prognosis. These cancers grow in response to hormones and are typically treated with hormone-blocking therapies.
- Triple-negative: About 11% of cases. These tumors don’t respond to hormones or overproduce HER2, which means fewer targeted treatment options. They tend to be more aggressive and are more common in younger women and Black women.
- Hormone receptor-positive, HER2-positive: About 9% of cases.
- Hormone receptor-negative, HER2-positive: About 4% of cases.
Both HER2-positive subtypes are now treated with targeted therapies that have dramatically improved outcomes over the past two decades.
Survival Rates by Stage
Stage at diagnosis is the single biggest factor in breast cancer survival. The five-year relative survival rates in the U.S., based on SEER data from 2016 to 2022:
- Localized (cancer confined to the breast): 100%
- Regional (spread to nearby lymph nodes): 87.5%
- Distant (metastatic, spread to other organs): 33.8%
That 100% figure for localized disease is remarkable and reflects decades of improvements in screening and treatment. Most breast cancers in the U.S. are caught at this early stage. The gap between localized and distant survival highlights why early detection matters so much. A cancer found before it has spread has a fundamentally different trajectory than one diagnosed after it reaches the bones, liver, lungs, or brain.
Racial Disparities in Survival
The numbers above are averages, and they mask significant inequities. Black women have a 4% lower incidence rate than White women, meaning they’re slightly less likely to be diagnosed. Yet they have a 40% higher death rate from the disease. Breast cancer is the leading cause of cancer death in both Black and Hispanic women, while it ranks second (behind lung cancer) for women overall.
The survival gap persists at every stage and every subtype. For regional-stage breast cancer, 88% of White women are alive five years after diagnosis compared to 78% of Black women. For metastatic disease, the gap is even starker: 32% versus 21%. American Indian and Alaska Native women show a similar pattern on a smaller scale. They’re 17% less likely to be diagnosed than White women but 4% more likely to die from it.
These disparities reflect a combination of factors: later-stage diagnosis due to lower screening access, higher rates of aggressive subtypes like triple-negative breast cancer, differences in treatment access and quality, and the cumulative health effects of systemic inequality. The biology of the tumors matters, but so does whether a person can get timely, high-quality care.